Wilson Martin sold 75,364 Rocket Pharmaceuticals shares at $3.40 per share on 2026-09-11, a transaction equal to about 11.2% of his prior holding. For investors, the disclosed transaction leaves Martin with 598,489 shares and identifies the scale of the sale relative to his own position.
Key Highlights
- Martin is identified as Rocket Pharmaceuticals’ general counsel.
- His post-transaction holding was 598,489 shares.
- The filing lists SEC transaction code S.
Wilson Martin sold 75,364 Rocket Pharmaceuticals shares at $3.40 per share on 11 September 2026, in a transaction representing about 11.2% of his prior holding.
General Counsel’s Share Sale
Martin is identified as general counsel of Rocket Pharmaceuticals. The filing lists SEC transaction code S. The reported transaction involved Rocket Pharmaceuticals shares and was dated 11 September 2026. The per-share price was $3.40, while the disclosed transaction quantity was 75,364 shares.
Post-Transaction Holding
Martin owned 598,489 shares after the transaction. The filing states that the transaction represented about 11.2% of his prior shareholding. Transaction code S denotes an open-market or private sale.
FAQs
Q: What did Wilson Martin sell in the Rocket Pharmaceuticals insider transaction?
A: Wilson Martin sold 75,364 Rocket Pharmaceuticals shares at $3.40 per share. The transaction occurred on 11 September 2026 and used SEC code S.
Q: How many Rocket Pharmaceuticals shares does Wilson Martin still own?
A: Wilson Martin owned 598,489 Rocket Pharmaceuticals shares after the transaction. The reported balance reflects his position following the sale. The filing reports this post-transaction ownership figure.
Q: What percentage of Wilson Martin’s prior holding did the sale represent?
A: The Rocket Pharmaceuticals share sale represented about 11.2% of Wilson Martin’s prior holding. The percentage is measured against his position before the transaction.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.